<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04236960</url>
  </required_header>
  <id_info>
    <org_study_id>008152017002</org_study_id>
    <nct_id>NCT04236960</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.</brief_title>
  <official_title>Phase I Clinical Study of Meningococcal Group ACYW135 Conjugate Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walvax Biotechnology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Walvax Biotechnology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-center and open-labeled Phase I study, designed to evaluate the safety by observing&#xD;
      the occurrence of adverse events and change of hematology, liver and renal function after&#xD;
      vaccination of a meningococcal group A, C, Y, and W135 conjugate vaccine in healthy&#xD;
      population aged 2 months to 55 years old.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Actual">November 28, 2019</completion_date>
  <primary_completion_date type="Actual">September 16, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events after each vaccination</measure>
    <time_frame>30 days after vaccination</time_frame>
    <description>Percentage of subjects with local and systemic adverse events after each dose of vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events after vaccination</measure>
    <time_frame>day 0 to 6 months after last dose</time_frame>
    <description>Percentage of subjects with serious adverse events from day 0 to 6 months after last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood routine in 2 years and above subjects</measure>
    <time_frame>3 days after vaccination</time_frame>
    <description>content of hemoglobin（g/dL）、white blood cell count（WBC）、blood platelet count（PLT）3 days after vaccination in 2 years and above subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function in 2 years and above subjects</measure>
    <time_frame>3 days after vaccination</time_frame>
    <description>Alanine aminotransferase（ALT），Aspartate aminotransferase（AST），Total bilirubin(TBIL) 3 days after vaccination in 2 years and above subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function in 2 years and above subjects</measure>
    <time_frame>3 days after vaccination</time_frame>
    <description>Creatinine（CR），Urea nitrogen（BUN）3 days after vaccination in 2 years and above subjects</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Meningococcal Infections</condition>
  <arm_group>
    <arm_group_label>18~55 yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2~17 yrs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 dose of meningococcal group ACYW135 conjugate vaccine will be administered on day 0.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7~23 mos</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between the first and second dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mos</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. One-month interval between every two doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mos</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 doses of meningococcal group ACYW135 conjugate vaccine will be administered. Two-month interval between every two doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Meningococcal Group ACYW135 Conjugate Vaccine</intervention_name>
    <description>1 dose in Stage 1 (2~55 yrs), 2 doses in Stage 2 (7~23 mos), and 3 doses in Stage 3 (2&amp;3 mos)</description>
    <arm_group_label>18~55 yrs</arm_group_label>
    <arm_group_label>2 mos</arm_group_label>
    <arm_group_label>2~17 yrs</arm_group_label>
    <arm_group_label>3 mos</arm_group_label>
    <arm_group_label>7~23 mos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy children, adolescents and adults (age range: 2 months to 55 years old) based&#xD;
             on medical history, physical examination or judgement of the investigator&#xD;
&#xD;
          -  Subjects aged ≥18 years old voluntarily agree to participate in this clinical study&#xD;
             and sign the informed consent form; or for subjects aged &lt;18 years old, the legal&#xD;
             guardian voluntarily agrees that his/her child to participate in this clinical study,&#xD;
             and sign the informed consent form. For juveniles aged ≥8 years old, both the subject&#xD;
             and his/her legal guardians should voluntarily agree to participate in this clinical&#xD;
             study and sign the informed consent form.&#xD;
&#xD;
          -  The subject and his/her legal guardians as well as the family members are able to&#xD;
             follow the request of clinical study protocol.&#xD;
&#xD;
          -  Subjects aged 2 or 3 months should have no vaccination history of any meningococcal&#xD;
             vaccine; subjects aged 7~23 months should have not received any other meningococcal&#xD;
             vaccine except the meningococcal group A polysaccharide vaccine included in National&#xD;
             Immunization Program, and the time since last vaccination of meningococcal group A&#xD;
             polysaccharide vaccine should be &gt;6 months; for subjects ≥2 years, the time since last&#xD;
             vaccination of meningococcal vaccine should be &gt;2 years.&#xD;
&#xD;
          -  For subjects aged ≥2 years, there should be no clinically significant abnormal&#xD;
             hematology, liver and renal function results judged by the investigator before&#xD;
             immunization.&#xD;
&#xD;
          -  Subjects should not receive any attenuated live vaccine 14 days, or inactivated&#xD;
             vaccine 7 days before or after vaccination.&#xD;
&#xD;
          -  Axillary temperature ≤37.0℃.&#xD;
&#xD;
        Exclusion Criteria for First Dose:&#xD;
&#xD;
          -  Subjects aged 2 or 3 months at enrollment with birth weight &lt;2.5 kg.&#xD;
&#xD;
          -  Subjects aged 2 or 3 months at enrollment had received blood products and immunoglobin&#xD;
             after birth; subjects of other age groups had received blood products or immunoglobin&#xD;
             in &lt;3 months before vaccination.&#xD;
&#xD;
          -  Subjects aged &lt;12 months at enrollment are diagnosed as with pathological jaundice or&#xD;
             have a history of pathological jaundice.&#xD;
&#xD;
          -  Subjects aged &lt;2 months at enrollment had abnormal labor (dystocia, assisted&#xD;
             instrumental delivery) or with the history of asphyxia or nervous damage.&#xD;
&#xD;
          -  Subjects aged ≥18 years who are planning pregnancy, or are pregnant, or are&#xD;
             breastfeeding.&#xD;
&#xD;
          -  Subjects aged ≥18 years with uncontrollable hypertension (during screening: systolic&#xD;
             BP &gt;140 mmHg or diastolic BP &gt;90 mmHg).&#xD;
&#xD;
          -  Subjects are known to be allergic to certain components contained in the&#xD;
             investigational vaccine (mainly include: capsular polysaccharide of meningococcal&#xD;
             group A, group C, group Y, or group W135, diphtheria toxoid or diphtheria antigen).&#xD;
&#xD;
          -  Subjects with the history of serious allergy to any vaccine or drug. (including but&#xD;
             not limited to: allergic shock, allergic laryngeal edema, allergic purpura,&#xD;
             thrombocytopenic purpura, local allergic necrosis reaction [Arthus reaction]).&#xD;
&#xD;
          -  Subjects with the history of meningitis.&#xD;
&#xD;
          -  Subjects with moderate to severe fever (axillary temperature ≥38.0℃) in last 3 days.&#xD;
&#xD;
          -  Subjects with the history or family history of convulsion, seizure, encephalopathy, or&#xD;
             psychiatric disorders.&#xD;
&#xD;
          -  Subjects with definite diagnosis of thrombocytopenia or other coagulation disorders.&#xD;
&#xD;
          -  Subjects with primary or secondary immunological dysfunction, including HIV infection,&#xD;
             disorder or resection of thyroid, pancreas, liver, spleen or kidney; or needed&#xD;
             treatment due to thyroid disorders in last 12 months (time interval &lt;12 months).&#xD;
&#xD;
          -  Subjects have received immunosuppressive therapy, cytotoxic therapy, corticosteroid&#xD;
             hormone (not include corticosteroid hormone spray for allergic rhinitis, epithelial&#xD;
             corticosteroid hormone for acute and non-complicated dermatitis) in last 6 months&#xD;
             (time interval &lt;6 months).&#xD;
&#xD;
          -  Subjects with known congenital malformation, developmental disabilities or clinically&#xD;
             confirmed serious chronic diseases (e.g., Down syndrome, diabetes mellitus, sickle&#xD;
             cell anemia or nervous disease, Guillain-Barre syndrome, etc.).&#xD;
&#xD;
          -  Subjects with known or suspected diseases that are likely to affect the vaccination by&#xD;
             investigators' judgement, such as: serious respiratory diseases, acute infection or&#xD;
             the active period of chronic disease, serious cardiovascular diseases, liver and renal&#xD;
             diseases, malignant tumors, serious infectious or allergic skin diseases.&#xD;
&#xD;
          -  Subjects are participating or plan to participate in other clinical trials of&#xD;
             investigational medications.&#xD;
&#xD;
          -  Any other conditions that may influence the evaluation of clinical study by&#xD;
             investigators' judgement.&#xD;
&#xD;
        Exclusion Criteria for Second and Third Dose:&#xD;
&#xD;
          -  New conditions that conforms with the exclusion criteria for first dose.&#xD;
&#xD;
          -  Subjects that develop grade 4 adverse reactions after vaccination of investigational&#xD;
             vaccine.&#xD;
&#xD;
          -  Subjects that develop serious allergic reactions after vaccination of investigational&#xD;
             vaccine.&#xD;
&#xD;
          -  Any other conditions that may influence the evaluation of clinical study by&#xD;
             investigators' judgement based on the exclusion criteria for first dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guangdong Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis, Meningococcal, Serogroup A</keyword>
  <keyword>Meningitis, Meningococcal, Serogroup C</keyword>
  <keyword>Meningitis, Meningococcal, Serogroup Y</keyword>
  <keyword>Meningitis, Meningococcal, Serogroup W135</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

